Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousHematologic NeoplasmsPeripheral Blood Stem Cell TransplantationTreatment OutcomeTransplantation ChimeraStem CellsGraft vs Leukemia EffectBone Marrow TransplantationTissue DonorsMyeloablative AgonistsBusulfanRecurrenceRemission InductionVidarabineSurvival RateGraft SurvivalRetrospective StudiesGraft vs Tumor EffectHistocompatibility TestingSurvival AnalysisDisease-Free SurvivalLymphocyte TransfusionImmunosuppressive AgentsCombined Modality TherapyLeukemia, Myeloid, AcuteLeukemiaMultiple MyelomaSiblingsCord Blood Stem Cell TransplantationCytomegalovirus InfectionsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSalvage TherapyTime FactorsLiver TransplantationHematopoietic Stem CellsMinor Histocompatibility AntigensWhole-Body IrradiationLymphocyte DepletionAntilymphocyte SerumMyelodysplastic SyndromesFollow-Up StudiesHistocompatibilityVirus ActivationNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisMelphalanChimerismAntineoplastic Combined Chemotherapy ProtocolsHepatic Veno-Occlusive DiseaseCyclophosphamideAcute DiseaseMesenchymal Stem Cell TransplantationCytomegalovirusT-LymphocytesHematopoietic Stem Cell MobilizationKidney TransplantationAnemia, AplasticPrimary MyelofibrosisCell TransplantationHLA AntigensHematologic DiseasesProspective StudiesEmbryonic Stem CellsLeukemia, Myeloid, Accelerated PhaseAntineoplastic AgentsAntigens, CD34ImmunosuppressionTransplantation ImmunologyCytarabineAntibodies, NeoplasmRisk FactorsRoseolovirus InfectionsBenzamidesImmunocompromised HostLymphoproliferative DisordersLeukemia, MyeloidGraft RejectionAdult Stem CellsFusion Proteins, bcr-ablHodgkin DiseasePyrimidinesCell SurvivalReceptors, Purinergic P2X5Nuclear FamilyGanciclovirLymphoma, Non-HodgkinInfectionFatal OutcomePiperazinesCyclosporineGranulocyte Colony-Stimulating FactorHeart TransplantationImmunotherapy, AdoptiveKaplan-Meier Estimate